Autosomal recessive ataxia due to PEX10 deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:247815G11.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Autosomal recessive ataxia due to PEX10 deficiency (also known as peroxisomal biogenesis disorder complementation group 7, or PEX10-related cerebellar ataxia) is a rare neurological condition caused by biallelic mutations in the PEX10 gene. The PEX10 gene encodes a peroxisomal membrane protein essential for peroxisome biogenesis and function. Peroxisomes are cellular organelles involved in the metabolism of very long-chain fatty acids, bile acid synthesis, and other critical biochemical pathways. Mutations in PEX10 can produce a spectrum of disease severity, ranging from severe neonatal forms within the Zellweger spectrum disorders to milder phenotypes presenting primarily as cerebellar ataxia in childhood or adulthood. In the milder ataxia-predominant form (Orphanet 247815), the primary body system affected is the central nervous system, particularly the cerebellum. Key clinical features include progressive cerebellar ataxia (impaired coordination and balance), sensorimotor neuropathy, and cerebellar atrophy visible on brain MRI. Patients may also experience hyperreflexia, dysarthria (slurred speech), oculomotor abnormalities, and cognitive difficulties. Some individuals may have subtle biochemical abnormalities of peroxisomal function, such as mildly elevated very long-chain fatty acids or abnormal phytanic acid levels, which can aid in diagnosis. There is currently no curative treatment for autosomal recessive ataxia due to PEX10 deficiency. Management is supportive and symptomatic, focusing on physical therapy and rehabilitation to maintain mobility and coordination, speech therapy for dysarthria, and occupational therapy for daily living activities. Monitoring of peroxisomal biochemical markers and neurological status is recommended. Genetic counseling is important for affected families. Research into peroxisomal disorders continues, but no disease-modifying therapies are currently available for this condition.

Also known as:

Clinical phenotype terms— hover any for plain English:

Motor axonal neuropathyHP:0007002Impaired smooth pursuitHP:0007772Very long chain fatty acid accumulationHP:0008167Abnormal circulating phytanic acid concentrationHP:0010965Diffuse cerebellar atrophyHP:0100275Abnormal head movementsHP:0002457MydriasisHP:0011499
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Autosomal recessive ataxia due to PEX10 deficiency.

View clinical trials →

No actively recruiting trials found for Autosomal recessive ataxia due to PEX10 deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Autosomal recessive ataxia due to PEX10 deficiency community →

No specialists are currently listed for Autosomal recessive ataxia due to PEX10 deficiency.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autosomal recessive ataxia due to PEX10 deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autosomal recessive ataxia due to PEX10 deficiencyForum →

No community posts yet. Be the first to share your experience with Autosomal recessive ataxia due to PEX10 deficiency.

Start the conversation →

Latest news about Autosomal recessive ataxia due to PEX10 deficiency

No recent news articles for Autosomal recessive ataxia due to PEX10 deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Autosomal recessive ataxia due to PEX10 deficiency

What is Autosomal recessive ataxia due to PEX10 deficiency?

Autosomal recessive ataxia due to PEX10 deficiency (also known as peroxisomal biogenesis disorder complementation group 7, or PEX10-related cerebellar ataxia) is a rare neurological condition caused by biallelic mutations in the PEX10 gene. The PEX10 gene encodes a peroxisomal membrane protein essential for peroxisome biogenesis and function. Peroxisomes are cellular organelles involved in the metabolism of very long-chain fatty acids, bile acid synthesis, and other critical biochemical pathways. Mutations in PEX10 can produce a spectrum of disease severity, ranging from severe neonatal forms

How is Autosomal recessive ataxia due to PEX10 deficiency inherited?

Autosomal recessive ataxia due to PEX10 deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.